A real-world, multicenter, observational, Population Pharmacokinetic (PK) Study of Two Recombinant Factor VIII (rFVIII) Concentrates in Boys with Severe Hemophilia a without Inhibitors
Latest Information Update: 17 Jan 2023
Price :
$35 *
At a glance
- Drugs Damoctocog alfa pegol (Primary) ; Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics
- 17 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition